ClinicalTrials.gg
Not yet recruitingNCT07472322Updated Oct 30, 2026

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

A Phase 1/2 interventional study of ASTX727 + retifanlimab in Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III and Merkel Cell Carcinoma, Stage IV, sponsored by University of Wisconsin, Madison. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of Wisconsin, Madison · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 30, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Carcinoma, Merkel Cell with a site in United States — 26 open to participants now, 47 under way, 3 of them phase 3. Carcinoma, Merkel Cell · United States.

Planned enrollment
60th of 105
31 · median 40
Started
2026
with 4 others
Phase 1/2
27 of 112
9 open now
Primary completion
2031-05
later than 43 of 46 live
Registered
111th of 112
by date

Among the 112 studies in Carcinoma, Merkel Cell with a site in United States, this one is the 60th largest by planned enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2026, is one of 27 in phase 1/2, reaches primary completion later than 43 of the 46 other live ones, and was the 111th registered.

Carcinoma, Merkel Cell

150 studies on the registry are indexed under Carcinoma, Merkel Cell; 39 are open to participants now.

Browse Carcinoma, Merkel Cell studies →

Open to participants now

26 of the 112 studies in Carcinoma, Merkel Cell with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Carcinoma, Merkel Cell studies recruiting now, 26 (79%) set no upper age limit and none (0%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Carcinoma, Merkel Cell with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are:

  • Can the combination shrink cancer and lower the chance of the cancer growing or spreading?
  • Is the combination better than standard of care for Merkel cell cancer?

Participants will:

  • Take oral ASTX727 and retifanlimab through a vein in the arm for about 2 years.
  • Visit the clinic once every 2 weeks for checkups and tests
Read the detailed description

This study is being done to see if combining ASTX727 (decitabine/cedazuridine) with retifanlimab-dlwr is safe and confers clinical benefit in patients with advanced Merkel cell carcinoma who have progressed on anti-PD-(L)1 inhibitor therapy.

03

Conditions studied

  • Merkel Cell Carcinoma
  • Merkel Cell Carcinoma, Stage III
  • Merkel Cell Carcinoma, Stage IV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals age ≥ 18 years at the time of consent
  • Performance Status of 0-2
  • Histological or cytological evidence/confirmation of Merkel cell carcinoma (MCC)
  • Must have unresectable stage III/IV MCC per American Joint Committee on Cancer (AJCC) 8th edition. Participants must be considered unresectable based on the judgment of the treating physician
  • Participants must have progressed on prior programmed cell death protein-1 () or programmed death-ligand 1(PD-L1) inhibitor-based therapy. Participants must have received at least 2 doses of anti-PD-1 or anti-PD-L1 inhibitor. disease from prior adjuvant PD-1 or PD-L1 inhibitor is permitted. Prior treatment with retifanlimab is permitted.
  • Demonstrate adequate organ and marrow function; all screening labs to be obtained within 28 days prior to registration

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a hypomethylating agent (HMA) (e.g., azacitidine, decitabine, guadecitabine)
  • History of intolerance, , or treatment discontinuation of an or anti-PD-L1 inhibitor due to grade 3 or greater immune-related adverse events (irAEs). Participants who are able to be successfully rechallenged with anti-PD-(L)1 inhibitor without recurrence of grade 3 or greater irAEs are permitted on study. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study drug(s) may be included (e.g. hearing loss, hypothyroidism, adrenal insufficiency, type 1 diabetes, or other endocrinopathies) after consultation with the sponsor investigator
  • Palliative radiation therapy administered within 1 week before the first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months before the first dose of study treatment
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to registration
  • Active infection requiring systemic therapy within 7 days prior to registration
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Merkel cell carcinoma

    Participants with unresectable Merkel cell carcinoma who progressed on prior PD-1 or PD-L1 inhibitor

    Drug: ASTX727 + retifanlimab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with treatment-emergent adverse events

    Adverse events will be measured using NCI Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Grade 3 or greater non-hematological, grade 4 or greater treatment-emergent AEs, and instances where treatment has to be discontinued will be calculated for this measure.

    Time frame: Up to 27 months (2 years plus 90 days)

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the proportion of subjects who have a partial response \[PR\] or complete response \[CR\] per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (1.1).

    Time frame: Up to 4 years

  2. Disease Control Rate (DCR)

    DCR is defined as the proportion of all subjects with RECIST-based PR, CR, and SD divided by the total number of evaluable participants.

    Time frame: Up to 4 years

  3. Progression-free Survival (PFS)

    PFS is defined as the interval from start of treatment to first documentation of disease progression per RECIST 1.1 or death from any cause. Participants who have not progressed will be right-censored at the date of the last disease evaluation

    Time frame: Up to 4 years

  4. Overall Survival (OS)

    OS is defined as the interval from start of treatment to death of any cause. Participants alive at last time of contact will be right-censored.

    Time frame: Up to 4 years

  5. Duration of Response (DoR)

    DoR is defined as the time from documentation of response (PR, CR) to treatment to the first documentation of tumor progression per RECIST 1.1 or death due to any cause, whichever comes first.

    Time frame: Up to 4 years

  6. Percentage of participants with tumor reduction

    At least a 30% decrease in the sum of the diameters of target lesions by RECIST v1.1.

    Time frame: Up to 4 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Researchers must have local IRB approval for their study that is to include study of the biospecimens and accompanying data. Release of biospecimens to non-UW researchers will be performed according to all UW regulatory policies. Tissue (including blood) specimen as part of this research will be primarily stored at UW and may be sent to an outside lab/facility to achieve the objectives of the study. No study data or patient health information will be shared with a third party.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Access criteria: Researchers who are doing biomedical research may apply to the PI for access to blood and tissue (no patient identifiers on tubes or slides). Only de-identified information will be released with the specimens

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for May 2031, 54 months later.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 16, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
May 2031
CompletionEst.
May 2031
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Nov 2026
moved 2 times, Sep 29, 2026 – Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    Start date Oct 2026→Nov 2026
  2. Sep 29, 2026
    Start date Sep 2026→Oct 2026
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07472322
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Oct 30, 2026

Study contacts

Cancer Connect
Contact
clinicaltrials@cancer.wisc.edu
800-622-8922
Renae Quale, RN
Contact
rmq@medicine.wisc.edu
Vincent Ma, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retifanlimab

Start the discussion